Nocturne Acquisition And Cognos Therapeutics Secure Chardan As Capital Markets Advisor For Business Combination
Portfolio Pulse from Benzinga Newsdesk
Nocturne Acquisition Corp. and Cognos Therapeutics have secured Chardan as their capital markets advisor for their upcoming business combination. The role of Chardan will be to provide strategic advice and assist in the execution of the transaction.
September 21, 2023 | 5:39 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Nocturne Acquisition Corp., which is expected to merge with Cognos Therapeutics, has secured Chardan as their capital markets advisor. This could potentially streamline the merger process and provide strategic insights.
The appointment of a capital markets advisor is a positive development for Nocturne Acquisition Corp. as it indicates progress in the merger process. Chardan's expertise could potentially streamline the merger process and provide strategic insights, which could positively impact the stock price in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100